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Background: Recognizing a change in serum creatinine concentrations is useful to
detect a renal adverse drug reaction signal. Assessing and characterizing the
nephrotoxic side-effects of drugs in extremely low birth weight (ELBW, ≤1000 g)
neonates remain challenging due to the high variability in creatinine in this population.
This study aims to investigate and quantify the impact of ibuprofen treatment on
kidney function, reflected by serum creatinine.
Method: A recently developed dynamical model for serum creatinine was used to simulate
creatinine profiles for typical, reference ELBW neonates with varying gestational and
postnatal ages whilst being exposed to ibuprofen treatment.
Results: The increase of serum creatinine concentrations due to ibuprofen treatment is
most apparent during the first week of life. The difference in serum creatinine values
between ibuprofen-exposed vs. non-exposed neonates decreases with increasing
postnatal age, independent of gestational age.
Conclusion: The difference in serum creatinine concentrations between ibuprofen-
exposed vs. non-exposed neonates decreases with postnatal age, indicating an
increased clearing capacity and resulting in a weak ibuprofen-related adverse drug
reaction signal beyond early neonatal life.
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INTRODUCTION
Extremely low birth weight (ELBW, ≤1,000 g) infants are born
during active nephrogenesis, making their kidneys extremely
vulnerable to damage by external factors such as exposure to
nephrotoxic drugs or diseases such as neonatal sepsis. Although
the development of nephrons will continue after preterm delivery,
the final amount of nephrons will be less for infants who are born
prematurely with an ELBW (Faa et al., 2010; Abitbol et al., 2016;
Hoogenboom et al., 2020).
Serum creatinine is commonly used as a surrogate biomarker
for glomerular filtration rate as well as to assess kidney injury.
Serum creatinine concentrations in preterm neonates are highly
variable due to rapid changes in maturation (i.e., developmental
physiology) and intercurrent events such as neonatal sepsis or
therapeutic interventions for neonatal diseases (Vieux et al., 2010;
George et al., 2011; van den Anker et al., 2018; Allegaert et al.,
2020). The variations in serum creatinine values in these extreme
preterm infants are still not fully understood and the accurate
assessment of kidney function remains challenging. Although
developed equations such as the (bedside) Schwartz formula
support clinicians in estimating the glomerular filtration rate
(GFR), the underlying physiology and the impact of
pharmacotherapy have not been fully elucidated for ELBW
neonates (Schwartz et al., 1976; Schwartz et al., 2009).
Recently, the quantitative effect of maturational changes such
as gestational age and postnatal age, together with the impact of
mode of delivery and ibuprofen treatment on the serum
creatinine in ELBW neonates, has been reported (van Donge
et al., 2020). This study showed that gestational age was a major
determinant of the initial creatinine concentration at birth,
suggesting gestational-dependent maternal creatinine transfer
until birth (van Donge et al., 2020).
The fundamental aspects of neonatal clinical pharmacology
such as exposure to a multitude of drugs, a highly variable
population as reflected by the 10-fold difference in birth
weight on admission: 0.5–5 kg, and rapid growth and
development result in extensive within- and between-subject
variability in drug disposition during the first months of life
(Allegaert et al., 2008; Allegaert et al., 2014). Ibuprofen, a
nonsteroidal anti-inflammatory drug (NSAID), is often
prescribed to preterm neonates as pharmacological treatment
of a symptomatic patent ductus arteriosus and is known for its
nephrotoxic side-effects (Mitra et al., 2018). The nephrotoxic
effects of ibuprofen are related to its mechanism of action
(i.e., inhibition of cyclooxygenase, resulting in decreased
prostaglandin synthesis) (Fanos et al., 2010). The induced
prostaglandin inhibition of ibuprofen may result in renal
hypoperfusion as prostaglandin E2, being synthesized along
the nephron, and contributes to the regulation of renal
perfusion and GFR by neutralizing the action of
vasoconstrictive substances such as angiotensin II (Fanos et al.,
2005; Antonucci and Fanos, 2009).
The aim of this study was to assess and quantify the effect of
ibuprofen on serum creatinine profiles of ELBW neonates of
various postnatal and gestational ages. This knowledge may
support the interpretation of serum creatinine values in this
neonatal subpopulation and inform clinicians on the kidney
function and potential kidney injury in their patients.
METHOD
Ethics
The studies involving human participants were reviewed and
approved by the Ethics Committee UZ/KU Leuven (S63405,
June 17, 2020). As this was a retrospective analysis of serum
creatinine and clinical data, written consent from the legal
guardians was not required to participate in this study in
accordance with the national legislation and the
institutional requirements.
Serum Creatinine Dynamic Model
We applied a recently published dynamic model that characterized
the serum creatinine concentrations for ELBW infants (van Donge
et al., 2020). The model was developed based on 4,026 serum
creatinine concentrations collected during the first 6 weeks of life in
217 ELBW neonates. The median gestational age and birth weight
were 27 weeks (26–28 weeks IQR) and 830 g (720–910 g IQR),
respectively. The mode of delivery and gestational age showed
an association with postnatal maturation of the creatinine
clearance (faster clearance increase with advancing GA and after
C-section). In this previous study, the elimination rate of creatinine
(ket) was characterized as ket  CL(t)Vd 
(CLBL+ emax × tHillt50 Hill+ tHill )
0.7( Lkg)× weight(kg)
, where
t reflects postnatal age (days), CLBL reflects baseline creatinine
clearance (L/day), emax is the maximum additional achieved
clearance (L/day), t50 corresponds to the time point where half
of emax is achieved, and the Hill coefficient describes the steepness
of the creatinine-time relationship. Additional details on the
dynamic model can be found in the original article (van Donge
et al., 2020). Ibuprofen treatment was included in the model on
creatinine clearance at baseline (CLBL) and accounted for a 5%
decrease when ibuprofen was administered [CLBLi  0.075 L/day ×
(1 + 2.55)]. The study showed that ibuprofen treatment is associated
with a decrease in creatinine clearance, whereas inotropic agents
were not associated with changes in serum creatinine or creatinine
clearance and therefore not included in the model. This study
provided new insights into the perinatal factors (related to
physiological and pathophysiological) affecting serum creatinine
and therefore influencing kidney function. The current study aims
to quantify the impact of ibuprofen treatment on serum creatinine
concentrations at various periods during early and late neonatal life,
addressing the potential adverse drug reactions of ibuprofen,
affected by postnatal maturation.
To illustrate the effect of ibuprofen treatment on serum
creatinine profiles in cases with different gestational and
postnatal ages, we simulated serum creatinine profiles during
ibuprofen exposure for four typical reference neonates with
varying gestational ages of 24, 27, 29, and 32 weeks,
respectively. Their respective birth weight amounted to 621,
779, 840, and 889 g. The ibuprofen treatment was comprised of
three different treatment periods of three consecutive days: either
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days 1–3 (first week of life), or day 15 to day 17 (third week of life),
or day 29 to day 31 (fifth week of life) after birth. BSA at the start of
the first treatment period (day 1) amounted to 0.07, 0.08, 0.09, and
0.09 m2, for our four typical reference neonates, respectively, and
BSA at the end of the third treatment period (day 31) was 0.09,
0.11, 0.11, and 0.12 m2. In the current dataset, ibuprofen was
administered according to the current label, i.e., 10, 5, and
5 mg/kg, respectively, at 24 h intervals. Simulations were
performed using the mlxR package in R (version 3.5.1; R
Development Core Team, Vienna, Austria, http://r-project.org),
with the inclusion of the population parameters derived of the
dynamic model, which was developed in Monolix (version
2019R1. Antony, France: Lixoft SAS, 2020, http://lixoft.com/
products/monolix/). We compared the predicted serum
creatinine concentration and creatinine clearance over a period
of 6 weeks after birth for typical reference ELBW cases who were
exposed to ibuprofen or not.
RESULTS
Serum Creatinine Dynamic Model
Predicted serum creatinine concentration profiles for four
typical reference ELBW neonates are shown in Figure 1.
Generally, an increase in serum creatinine concentrations is
observed during treatment with ibuprofen, with a more
pronounced effect during the early neonatal life, i.e., the first
week of life. The difference in the serum creatinine
concentrations between patients receiving ibuprofen and non-
exposed patients decreases with postnatal age; this trend is
independent of gestational age (Table 1). Table 2 illustrates
the serum creatinine concentrations for the four different
gestational ages, separated by the presence or absence of
ibuprofen treatment for the three different postnatal periods
(week 1, 3, or 5 after birth).
The extent of the increase of serum creatinine concentrations
due to ibuprofen treatment is the most pronounced during the
first week of life (i.e., round 1). For instance, for a neonate born at
24 weeks of gestation, the creatinine concentrations increase from
0.383 to 0.906 or 0.876 mg/dl in the presence or absence of
ibuprofen treatment, respectively (Table 2). This elevation of
creatinine concentrations is less pronounced later in life, as the
difference in creatinine concentrations between ibuprofen
treatment and the baseline is practically negligible for weeks 3
and 5 after birth (Table 1).
Focusing on the different gestational ages, the initial
increase in serum creatinine concentrations as observed
during the 5 days of life is most profound in the more
immature neonates. This elevation of creatinine
concentrations is the highest in extremely premature
neonates (an increase of 0.03 mg/dl for a 24-week-old
neonate) and decreases with gestational age (an increase of
FIGURE 1 | Predicted serum creatinine concentration-time profiles for four typical reference GA ELBW neonates: dotted lines represent serum creatinine
concentration under ibuprofen treatment; solid line represents the absence of ibuprofen treatment. GA, gestational age; ELBW, extremely low birth weight.
TABLE 1 | Differences in serum creatinine concentration (mg/dl) calculated at the
end of the treatment period for three ibuprofen treatment periods starting at
different postnatal ages and separated per gestational age group.
Differences in creatinine concentration (mg/dl)






24 weeks 0.030 0.010 0.006
27 weeks 0.026 0.008 0.005
29 weeks 0.025 0.007 0.005
32 weeks 0.023 0.006 0.004
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0.02 mg/dl for a 32-week-old neonate, Table 1). Figure 2
illustrates the increasing clearance capacities during the
postnatal period for ELBW neonates, depending on
gestational age. Creatinine clearance is reduced when the
neonate is exposed to ibuprofen, but this decrease is
proportionally much more relevant in the first week of
postnatal life. The reduction in creatinine clearance is
assumed to be absolute (−0.0094 ml/min), indicating no
difference between gestational and postnatal age. The
reduction in creatinine clearance due to ibuprofen
treatment is therefore proportionally higher in the early days
after birth (−5%), when clearance capacity is much limited, as
compared to week 5 after birth (approximately −2%).
DISCUSSION
This simulation study illustrated that the effect of ibuprofen
treatment is most apparent during the first week of life,
independent of gestational age. This difference in serum
creatinine concentrations decreases with postnatal age,
illustrating the increased renal clearance capacity during the
early weeks of life and simultaneous blunting of the
ibuprofen-related adverse drug reaction signal.
During the first days after birth, many physiological,
maturational, and potential pathological processes occur. The
increase in serum creatinine concentrations during the first days
after birth is the net phenotypic result of limited clearance
TABLE 2 | Serum creatinine concentrations (mg/dl) for different gestational ages, exposed to ibuprofen treatment or without ibuprofen treatment. Separated for three
treatment periods, starting at day 1, day 15, and day 29 of postnatal life and lasting for 3 days.
Creatinine concentration (mg/dl)
Period 1 (days 1–3) Period 2 (days 15–17) Period 3 (days 29–31)
Before After Before After Before After
Gestational age of 24 weeks
Ibuprofen 0.383 0.906 0.500 0.472 0.375 0.371
No ibuprofen 0.383 0.876 0.500 0.462 0.375 0.365
Gestational age of 27 weeks
Ibuprofen 0.462 0.857 0.439 0.419 0.345 0.344
No ibuprofen 0.462 0.830 0.439 0.411 0.345 0.339
Gestational age of 29 weeks
Ibuprofen 0.518 0.832 0.408 0.391 0.334 0.333
No ibuprofen 0.518 0.807 0.408 0.384 0.334 0.328
Gestational age of 32 weeks
Ibuprofen 0.607 0.795 0.374 0.360 0.321 0.322
No ibuprofen 0.607 0.772 0.374 0.355 0.321 0.318
FIGURE 2 | Predicted creatinine clearance profiles for four typical reference GA ELBW neonates: dotted lines represent creatinine clearance under ibuprofen
treatment; solid line represents the absence of ibuprofen treatment. GA, gestational age; ELBW, extremely low birth weight.
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capacities, drug exposure, tubular reabsorption (due to leaky
tubules), maternal creatinine transfer, and/or neonatal
comorbidities. It remains challenging to disentangle these
contributing components.
A previous study showed that the half-life of amikacin in
preterm neonates with a gestational age less than 31 weeks, who
received either ibuprofen or placebo, was significantly higher in
the patients who received ibuprofen (16.4 vs. 14.2 h) in early
neonatal life (Allegaert et al., 2004). Similar results were also
observed for amikacin clearance (0.36 vs. 0.6 ml/kg/min),
indicating that ibuprofen reduces the clearance of amikacin.
Being aware of the fact that amikacin is eliminated completely
by glomerular filtration, these findings can also be applied to the
clearance of creatinine (Allegaert et al., 2004). It has to be
acknowledged that these data were generated in the first
3 days of postnatal age (<72 h after birth); therefore, the
magnitude of this negative effect of ibuprofen exposure to the
glomerular filtration cannot simply be extrapolated beyond this
age. The current study confirmed that ibuprofen has a more
pronounced effect on the serum creatinine concentrations (and
GFR) when exposed during the first week of life as compared to
later in neonatal life.
Vieux et al. illustrated that, among all drugs that are
potentially nephrotoxic in very preterm infants, ibuprofen
alone proved nephrotoxic (decrease in estimated GFR) at
one-month follow-up (Vieux et al., 2011). Besides the type
of drug, the amount of administered drugs are as well of
relevance; it has been shown that very low birth weight
infants with acute kidney injury received more nephrotoxic
drugs than those who did not, as illustrated by Rhone et al.
(2014). In contrast, long-term outcome data on renal function
in young adolescence provided evidence that there is no
persistent effect of ibuprofen exposure in former ELBW
cases (Raaijmakers et al., 2018).
Observing a substantial increase of serum creatinine after birth
for an ELBW neonate could reflect a pathological condition
associated with an adverse drug reaction rather than the
immaturity of the kidney. Along the same line, the absence of
a decline in serum creatinine concentrations during the postnatal
period might reflect impaired glomerular filtration and thus
diminished kidney function. Although this study is not
focusing on acute kidney injury, it needs to be acknowledged
that physiological maturational events (i.e., adaptation to
extrauterine life) early after birth cause serum creatinine
concentrations to change, irrespective of (acute) kidney injury.
Therefore, we emphasize incorporating annotations related to
neonatal physiology in the definition of acute kidney injury.
Furthermore, the recognition of drug toxicity signals in
neonates, together with the extent of the adverse effect of
ibuprofen, is also related to the postnatal age.
The small fluctuations that are being observed in creatinine
concentrations and clearance can be identified as a limitation,
albeit this study illustrates the impact of both maturational and
non-maturational related effects, such as ibuprofen treatment
on kidney function, which can help in recognizing an adverse
drug reaction. In addition, the mechanism of action of
ibuprofen is related to its nephrotoxic side-effects, making
it challenging to disentangle the hemodynamically (“steal
phenomenon”) and nephrotoxic effects (suppression
prostaglandin synthesis) ibuprofen possesses. Both are
related to aspects of renal perfusion.
We have captured the phenotypic pattern in the model, so we
can only speculate the mechanistic contribution of either vascular
steal or suppression of prostaglandin synthesis. The fact that
ibuprofen clearance itself also increases with postnatal age, so that
a maturational decrease in ibuprofen exposure may also be
involved, further adds to the uncertainty of mechanisms
involved (Engbers et al., 2020).
The implementation of measures to prevent or minimize
nephrotoxicity and close monitoring of kidney functions are
mandatory in the ELBW neonate treated with ibuprofen or
other NSAIDs. Due to the substantial renal adverse drug
reactions, it is essential to take into account the benefit-risk
ratio when considering ibuprofen therapy (Bagnoli et al.,
2013). The potential adverse drug reaction of ibuprofen
affecting the kidney by a reduction of glomerular filtration is
thought to depend on the degree of maturation of the neonate.
Monitoring of serum creatinine concentrations, especially during
the first week of life, is essential to early detect these maturational
adverse drug reactions. After the first week of life, the effect can
still be observed and quantified but is proportionally much more
blunted (Figures 1, 2).
In conclusion, this study illustrates that the difference in serum
creatinine concentrations decreases with postnatal age, indicating
increased clearance capacity over time (gestational and postnatal
age) and demonstrates the magnitude of the ibuprofen-related
adverse drug reaction signals. Recognizing a change in creatinine
concentrations might be useful in recognizing an adverse drug
reaction signal after the start of ibuprofen treatment in ELBW
neonates, but this signal is more pronounced in early
neonatal life.
DATA AVAILABILITY STATEMENT
The raw data supporting the conclusions of this article will be
made available by the authors, without undue reservation.
Requests to access these data should be directed to
karel.allegaert@uzleuven.be.
ETHICS STATEMENT
The studies involving human participants were reviewed and
approved by UZ Leuven, ec@uzleuven.be. Written informed
consent from the participants’ legal guardians was not
required to participate in this study in accordance with the
national legislation and the institutional requirements.
AUTHOR CONTRIBUTIONS
TD, KA, and JA contributed to the conception and design of
the study. TD performed the analysis and generated tables and
Frontiers in Pharmacology | www.frontiersin.org January 2021 | Volume 11 | Article 6102945
van Donge et al. Ibuprofen Affects Maturational Creatinine Trends
figures. TD, KA, and JA wrote the first draft of the manuscript.
KA, MP, AS, and JA contributed to the interpretation of the
data and substantially revised the manuscript. All authors
contributed to manuscript revision and approved the
submitted version.
FUNDING
TD, MP, and JA are funded by the Eckenstein-Geigy foundation.
The research activities of AS are supported by the Clinical Research
and Education Council of the University Hospitals Leuven.
REFERENCES
Abitbol, C. L., Defreitas, M. J., and Strauss, J. (2016). Assessment of kidney function
in preterm infants: lifelong implications. Pediatr. Nephrol. 31, 2213–2222.
doi:10.1007/s00467-016-3320-x
Allegaert, K., Cossey, V., Langhendries, J., Naulaers, G., Vanhole, C., Devlieger, H.,
et al. (2004). Effects of co-administration of ibuprofen-lysine on the
pharmacokinetics of amikacin in preterm infants during the first days of
life. Biol. Neonate 86, 207–211. doi:10.1159/000079618
Allegaert, K., van de Velde, M., and van den Anker, J. (2014). Neonatal clinical
pharmacology. Paediatr. Anaesth. 24, 30–38. doi:10.1111/pan.12176
Allegaert, K., Verbesselt, R., Naulaers, G., van den Anker, J., Rayyan, M., Debeer,
A., et al. (2008). Developmental pharmacology: neonates are not just small
adults. Acta Clin. Belg. 63, 16–24. doi:10.1179/acb.2008.003
Allegaert, K., Smits, A., van Donge, T., van den Anker, J., Sarafidis, K., Levtchenko,
E., et al. (2020). Renal precision medicine in neonates and acute kidney injury:
how to convert a cloud of creatinine observations to support clinical decisions.
Front. Pediatr. 8, 366. doi:10.3389/fped.2020.00366
Antonucci, R., and Fanos, V. (2009). NSAIDs, prostaglandins and the neonatal
kidney. J. Matern. Fetal Neonatal Med. 22 (Suppl. 3), 23–26. doi:10.1080/
14767050903184447
Bagnoli, F., Rossetti, A., Messina, G., Mori, A., Casucci, M., and Tomasini, B.
(2013). Treatment of patent ductus arteriosus (PDA) using ibuprofen: renal
side-effects in VLBW and ELBW newborns. J. Matern. Fetal Neonatal Med. 26,
423–429. doi:10.3109/14767058.2012.733775
Engbers, A. G., Flint, R. B., Völler, S., De Klerk, J. C., Reiss, I. K., Andriessen, P.,
et al. (2020). Enantiomer specific pharmacokinetics of ibuprofen in preterm
neonates with patent ductus arteriosus. Br. J. Clin. Pharmacol. 86 (10),
2028–2039. doi:10.1111/bcp.14298
Faa, G., Gerosa, C., Fanni, D., Nemolato, S., Locci, A., Cabras, T., et al. (2010).
Marked interindividual variability in renal maturation of preterm infants:
lessons from autopsy. J. Matern. Fetal Neonatal Med. 23 (Suppl. 3),
129–133. doi:10.3109/14767058.2010.510646
Fanos, V., Antonucci, R., and Zaffanello, M. (2010). Ibuprofen and acute kidney
injury in the newborn. Turk. J. Pediatr. 52, 231–238.
Fanos, V., Benini, D., Verlato, G., Errico, G., and Cuzzolin, L. (2005). Efficacy and
renal tolerability of ibuprofen vs. indomethacin in preterm infants with patent
ductus arteriosus. Fundam. Clin. Pharmacol. 19, 187–193. doi:10.1111/j.1472-
8206.2004.00314.x
George, I., Mekahli, D., Rayyan, M., Levtchenko, E., and Allegaert, K. (2011).
Postnatal trends in creatinemia and its covariates in extremely low birth weight
(ELBW) neonates. Pediatr. Nephrol. 26, 1843–1849. doi:10.1007/s00467-011-
1883-0
Hoogenboom, L. A., Wolfs, T. G., Hütten, M. C., Peutz-Kootstra, C. J., and
Schreuder, M. F. (2020). Prematurity, perinatal inflammatory stress, and the
predisposition to develop chronic kidney disease beyond oligonephropathy.
Pediatr. Nephrol. doi:10.1007/s00467-020-04712-2
Mitra, S., Florez, I. D., Tamayo, M. E., Mbuagbaw, L., Vanniyasingam, T., Veroniki,
A. A., et al. (2018). Association of placebo, indomethacin, ibuprofen, and
acetaminophen with closure of hemodynamically significant patent ductus
arteriosus in preterm infants: a systematic review and meta-analysis. JAMA.
319, 1221–1238. doi:10.1001/jama.2018.1896
Raaijmakers, A., Zhang, Z. Y., Levtchenko, E., Simons, S. H., Cauwenberghs, N.,
Heuvel, L. P. V. D., et al. (2018). Ibuprofen exposure in early neonatal life does
not affect renal function in young adolescence. Arch. Dis. Child. Fetal Neonatal
Ed. 103, F107–F111. doi:10.1136/archdischild-2017-312922
Rhone, E. T., Carmody, J. B., Swanson, J. R., and Charlton, J. R. (2014).
Nephrotoxic medication exposure in very low birth weight infants.
J. Matern. Fetal Neonatal Med. 27, 1485–1490. doi:10.3109/14767058.2013.
860522
Schwartz, G. J., Haycock, G. B., Edelmann, C. M., and Spitzer, A. (1976). A simple
estimate of glomerular filtration rate in children derived from body length and
plasma creatinine. Pediatrics 58, 259–263.
Schwartz, G. J., Muñoz, A., Schneider, M. F., Mak, R. H., Kaskel, F., Warady, B. A.,
et al. (2009). New equations to estimate GFR in children with CKD. J. Am. Soc.
Nephrol. 20, 629–637. doi:10.1681/ASN.2008030287
van den Anker, J., Reed, M. D., Allegaert, K., and Kearns, G. L. (2018).
Developmental changes in pharmacokinetics and pharmacodynamics.
J. Clin. Pharmacol. 58, S10–S25. doi:10.1002/jcph.1284
van Donge, T., Allegaert, K., Gotta, V., Smits, A., Levtchenko, E., Mekahli, D., et al.
(2020). Characterizing dynamics of serum creatinine and creatinine clearance
in extremely low birth weight neonates during the first 6 weeks of life. Pediatr.
Nephrol. doi:10.1007/s00467-020-04749-3
Vieux, R., Fresson, J., Guillemin, F., and Hascoet, J. (2011). Perinatal drug exposure
and renal function in very preterm infants. Arch. Dis. Child. Fetal Neonatal Ed.
96, F290–F295. doi:10.1136/adc.2009.197699
Vieux, R., Hascoet, J. M., Merdariu, D., Fresson, J., and Guillemin, F. (2010).
Glomerular filtration rate reference values in very preterm infants. Pediatrics
125, e1186–e1192. doi:10.1542/peds.2009-1426
Conflict of Interest: The authors declare that the research was conducted in the
absence of any commercial or financial relationships that could be construed as a
potential conflict of interest.
Copyright © 2021 van Donge, Allegaert, Pfister, Smits and van den Anker. This is an
open-access article distributed under the terms of the Creative Commons Attribution
License (CC BY). The use, distribution or reproduction in other forums is permitted,
provided the original author(s) and the copyright owner(s) are credited and that the
original publication in this journal is cited, in accordance with accepted academic
practice. No use, distribution or reproduction is permitted which does not comply
with these terms.
Frontiers in Pharmacology | www.frontiersin.org January 2021 | Volume 11 | Article 6102946
van Donge et al. Ibuprofen Affects Maturational Creatinine Trends
